Immunomodulator Conjugates for Selective TLR7/8 Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine adjuvants, such as imiquimod and resiquimod, face limitations due to their reliance on specific Toll-like receptors (TLR) expression patterns and induce an imbalance of pro-inflammatory and anti-inflammatory cytokines, which restricts their efficacy in eliciting robust immune responses, especially in cancer treatment.
Innovation Solution
Development of imquidazolequinoline-based compounds that selectively activate TLR7 and TLR8, and potentially the inflammasome, to achieve a more favorable cytokine profile, enhancing antigen-specific immune responses by direct conjugation to antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current vaccine adjuvants (imiquimod, resiquimod) are used to stimulate immune response, then TLR signaling is activated, but the efficacy is limited due to reliance on specific TLR expression patterns and induction of anti-inflammatory cytokines
Solution Approach 1:
The patent segments the adjuvant function by developing separate compounds that selectively target different Toll-like receptors (TLR7, TLR8, TLR9). Instead of relying on a single adjuvant that must work through specific TLR expression patterns, the invention divides the immune stimulation task into multiple specialized components that can be matched to different APC subsets based on their TLR expression profiles.
Solution Approach 2:
The patent creates a universal platform for immune stimulation by developing compounds that can activate multiple TLR pathways (TLR7, TLR8, TLR9) depending on which receptors are expressed on the APCs present in different tissue sites or disease contexts. This multi-functional approach allows the same class of compounds to adapt to varying TLR expression patterns across different immune environments.
2Reliability
If imiquimod or resiquimod is administered to induce proinflammatory cytokines, then immune activation occurs, but anti-inflammatory cytokines are also induced which limits efficacy
Solution Approach 1:
The patent converts the harmful effect of anti-inflammatory cytokine induction into a beneficial outcome by designing compounds that selectively activate proinflammatory TLR pathways while avoiding or minimizing anti-inflammatory responses. The invention exploits the differential signaling capabilities of different TLRs to achieve immune activation without the counterproductive induction of IL-10 and other anti-inflammatory mediators that limit the efficacy of conventional adjuvants.
Solution Approach 2:
The patent changes the molecular parameters of the adjuvant compounds by developing novel imidazoquinoline and related structures with modified chemical groups and configurations that alter their receptor specificity. These parameter changes enable selective activation of TLR7, TLR8, or TLR9 with different cytokine induction profiles, allowing optimization of the proinflammatory to anti-inflammatory cytokine ratio.
3Reliability
If TLR ligand and antigen are co-administered in mixture, then APCs may engulf both components, but signal to noise ratio is reduced and timing is critical
Solution Approach 1:
The patent merges the TLR ligand and antigen into a single conjugate molecule, eliminating the need for separate administration and ensuring that every antigen molecule is paired with an immunostimulatory TLR ligand. This merging approach guarantees that APCs that take up the antigen also receive the TLR stimulation signal, eliminating the signal-to-noise problems associated with mixture administration where APCs may engulf only one component.
Solution Approach 2:
The patent uses a linker molecule as an intermediary to connect the TLR ligand to the antigen. This intermediary component facilitates the controlled delivery of both components to the same APC simultaneously, ensuring proper timing and spatial co-localization without requiring separate administration events. The linker acts as a mediator that coordinates the presentation of both the antigen and the immunostimulatory signal.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds improve the immune response by promoting a desirable ratio of pro-inflammatory to anti-inflammatory cytokines, increasing antigen-specific T cell activation and antibody production, thereby improving vaccine efficacy against cancer and infectious diseases.
Implementation Method 1
These compounds selectively activate TLR7 and TLR8, and potentially the inflammasome, to achieve a more favorable cytokine profile
Implementation Method 2
Imiquimod exerts its immunostimulatory effects through TLR 7 expressed on plasmacytoid dendritic cells and B cells in humans. Imiquimod treatment causes release of proinflammatory cytokines including interferonα, interferonγ, and IL-12
Implementation Method 3
enhancing antigen-specific immune responses by direct conjugation to antigens
Data Source
AI summary
The invention provides a method for stimulating an immune response in an animal with a compound of formula:or a pharmaceutically acceptable salt thereof, wherein R1-R3, Ra, and Rb have any of the values defined herein.